Novartis has bought Vedere Bio, a retinal disease therapy spinout of UC Berkeley also exploiting UPenn research, to expand its gene medicine capabilities.

Vedere Bio, a Switzerland-based genetic retinal disease therapy spinout of University of California, Berkeley, was acquired by pharmaceutical firm Novartis for up to $280m today. The amount includes a $150m upfront payment in addition to as much as $130m in milestone payments. Founded in 2019, Vedere Bio is developing gene therapies for inherited retinal dystrophies,…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.